124 related articles for article (PubMed ID: 17375138)
1. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.
Haupt DW; Fahnestock PA; Flavin KA; Schweiger JA; Stevens A; Hessler MJ; Maeda J; Yingling M; Newcomer JW
Neuropsychopharmacology; 2007 Dec; 32(12):2561-9. PubMed ID: 17375138
[TBL] [Abstract][Full Text] [Related]
2. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia.
Newcomer JW; Haupt DW; Fucetola R; Melson AK; Schweiger JA; Cooper BP; Selke G
Arch Gen Psychiatry; 2002 Apr; 59(4):337-45. PubMed ID: 11926934
[TBL] [Abstract][Full Text] [Related]
3. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.
Ader M; Garvey WT; Phillips LS; Nemeroff CB; Gharabawi G; Mahmoud R; Greenspan A; Berry SA; Musselman DL; Morein J; Zhu Y; Mao L; Bergman RN
J Psychiatr Res; 2008 Oct; 42(13):1076-85. PubMed ID: 18295798
[TBL] [Abstract][Full Text] [Related]
4. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
5. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
6. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.
Henderson DC; Fan X; Sharma B; Copeland PM; Borba CP; Freudenreich O; Cather C; Evins AE; Goff DC
J Psychiatr Pract; 2009 Jul; 15(4):251-61. PubMed ID: 19625881
[TBL] [Abstract][Full Text] [Related]
7. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia.
Haupt DW; Luber A; Maeda J; Melson AK; Schweiger JA; Newcomer JW
Neuropsychopharmacology; 2005 Jan; 30(1):184-91. PubMed ID: 15367925
[TBL] [Abstract][Full Text] [Related]
8. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Copeland PM; Borba CP; Daley TB; Nguyen DD; Cagliero E; Evins AE; Zhang H; Hayden DL; Freudenreich O; Cather C; Schoenfeld DA; Goff DC
J Clin Psychiatry; 2006 May; 67(5):789-97. PubMed ID: 16841629
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotics and glucose homeostasis.
Bergman RN; Ader M
J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
[TBL] [Abstract][Full Text] [Related]
10. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
11. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
[TBL] [Abstract][Full Text] [Related]
12. Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics.
Sapra M; Lawson D; Iranmanesh A; Varma A
Schizophr Res; 2016 Jul; 174(1-3):132-136. PubMed ID: 27211515
[TBL] [Abstract][Full Text] [Related]
13. Beta-cell Function and Metabolic Clearance Rate of Glucose in Patients with Major Mental Health Disorders on Antipsychotic Drug Treatment.
Akinlade KS; Rahamon SK; Lasebikan VO
J Natl Med Assoc; 2018 Oct; 110(5):504-511. PubMed ID: 30129504
[TBL] [Abstract][Full Text] [Related]
14. Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.
Guina J; Gupta A; Langleben DD; Elman I
J Clin Psychiatry; 2016 Dec; 77(12):e1650-e1651. PubMed ID: 28086013
[No Abstract] [Full Text] [Related]
15. Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.
Vincenzi B; Greene CM; Ulloa M; Parnarouskis L; Jackson JW; Henderson DC
J Psychiatr Pract; 2016 May; 22(3):175-82. PubMed ID: 27123797
[TBL] [Abstract][Full Text] [Related]
16. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.
Smith RC; Lindenmayer JP; Bark N; Warner-Cohen J; Vaidhyanathaswamy S; Khandat A
Int J Neuropsychopharmacol; 2005 Jun; 8(2):183-94. PubMed ID: 15737248
[TBL] [Abstract][Full Text] [Related]
17. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.
Cohen D; Stolk RP; Grobbee DE; Gispen-de Wied CC
Diabetes Care; 2006 Apr; 29(4):786-91. PubMed ID: 16567816
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
20. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
